Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione

Liliana Manciu, Xiu-Bao D Chang, Frédéric Buyse, Yue Xian Hou, Adelin Gustot, John R. Riordani, Jean Marie Ruysschaert

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Human multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette transporter family and transports chemotherapeutic drugs as well as diverse organic anions such as leukotriene LTC4. The transport of chemotherapeutic drugs requires the presence of reduced GSH. By using hydrogen/deuterium exchange kinetics and limited trypsin digestion, the structural changes associated with each step of the drug transport process are analyzed. Purified MRP1 is reconstituted into lipid vesicles with an inside-out orientation, exposing its cytoplasmic region to the external medium. The resulting proteoliposomes have been shown previously to exhibit both ATP-dependent drug transport and drug-stimulated ATPase activity. Our results show that during GSH-dependent drug transport, MRP1 does not undergo secondary structure changes but only modifications in its accessibility toward the external environment. Drug binding induces a restructuring of MRP1 membrane-embedded domains that does not affect the cytosolic domains, including the nucleotide binding domains, responsible for ATP hydrolysis. This demonstrates that drug binding to MRP1 is not sufficient to propagate an allosteric signal between the membrane and the cytosolic domains. On the other hand, GSH binding induces a conformational change that affects the structural organization of the cytosolic domains and enhances ATP binding and/or hydrolysis suggesting that GSH-mediated conformational changes are required for the coupling between drug transport and ATP hydrolysis. Following ATP binding, the protein adopts a conformation characterized by a decreased stability and/or an increased accessibility toward the aqueous medium. No additional change in the accessibility toward the solvent and/or the stability of this specific conformational state and no change of the transmembrane helices orientation are observed upon ATP hydrolysis. Binding of a non-transported drug affects the dynamic changes occurring during ATP binding and hydrolysis and restricts the movement of the drug and its release.

Original languageEnglish (US)
Pages (from-to)3347-3356
Number of pages10
JournalJournal of Biological Chemistry
Volume278
Issue number5
DOIs
StatePublished - Jan 31 2003

Fingerprint

P-Glycoprotein
Glutathione
Adenosine Triphosphate
Pharmaceutical Preparations
Hydrolysis
Leukotriene C4
Membranes
ATP-Binding Cassette Transporters
Leukotrienes
Deuterium
Trypsin
Anions
Adenosine Triphosphatases
Digestion
Hydrogen
Conformations
Nucleotides
Carrier Proteins
Lipids
Kinetics

ASJC Scopus subject areas

  • Biochemistry

Cite this

Manciu, L., Chang, X-B. D., Buyse, F., Hou, Y. X., Gustot, A., Riordani, J. R., & Ruysschaert, J. M. (2003). Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. Journal of Biological Chemistry, 278(5), 3347-3356. https://doi.org/10.1074/jbc.M207963200

Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. / Manciu, Liliana; Chang, Xiu-Bao D; Buyse, Frédéric; Hou, Yue Xian; Gustot, Adelin; Riordani, John R.; Ruysschaert, Jean Marie.

In: Journal of Biological Chemistry, Vol. 278, No. 5, 31.01.2003, p. 3347-3356.

Research output: Contribution to journalArticle

Manciu, L, Chang, X-BD, Buyse, F, Hou, YX, Gustot, A, Riordani, JR & Ruysschaert, JM 2003, 'Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione', Journal of Biological Chemistry, vol. 278, no. 5, pp. 3347-3356. https://doi.org/10.1074/jbc.M207963200
Manciu, Liliana ; Chang, Xiu-Bao D ; Buyse, Frédéric ; Hou, Yue Xian ; Gustot, Adelin ; Riordani, John R. ; Ruysschaert, Jean Marie. / Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione. In: Journal of Biological Chemistry. 2003 ; Vol. 278, No. 5. pp. 3347-3356.
@article{8a52d36b4b2a477a9029a09202ea99e8,
title = "Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione",
abstract = "Human multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette transporter family and transports chemotherapeutic drugs as well as diverse organic anions such as leukotriene LTC4. The transport of chemotherapeutic drugs requires the presence of reduced GSH. By using hydrogen/deuterium exchange kinetics and limited trypsin digestion, the structural changes associated with each step of the drug transport process are analyzed. Purified MRP1 is reconstituted into lipid vesicles with an inside-out orientation, exposing its cytoplasmic region to the external medium. The resulting proteoliposomes have been shown previously to exhibit both ATP-dependent drug transport and drug-stimulated ATPase activity. Our results show that during GSH-dependent drug transport, MRP1 does not undergo secondary structure changes but only modifications in its accessibility toward the external environment. Drug binding induces a restructuring of MRP1 membrane-embedded domains that does not affect the cytosolic domains, including the nucleotide binding domains, responsible for ATP hydrolysis. This demonstrates that drug binding to MRP1 is not sufficient to propagate an allosteric signal between the membrane and the cytosolic domains. On the other hand, GSH binding induces a conformational change that affects the structural organization of the cytosolic domains and enhances ATP binding and/or hydrolysis suggesting that GSH-mediated conformational changes are required for the coupling between drug transport and ATP hydrolysis. Following ATP binding, the protein adopts a conformation characterized by a decreased stability and/or an increased accessibility toward the aqueous medium. No additional change in the accessibility toward the solvent and/or the stability of this specific conformational state and no change of the transmembrane helices orientation are observed upon ATP hydrolysis. Binding of a non-transported drug affects the dynamic changes occurring during ATP binding and hydrolysis and restricts the movement of the drug and its release.",
author = "Liliana Manciu and Chang, {Xiu-Bao D} and Fr{\'e}d{\'e}ric Buyse and Hou, {Yue Xian} and Adelin Gustot and Riordani, {John R.} and Ruysschaert, {Jean Marie}",
year = "2003",
month = "1",
day = "31",
doi = "10.1074/jbc.M207963200",
language = "English (US)",
volume = "278",
pages = "3347--3356",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "5",

}

TY - JOUR

T1 - Intermediate structural states involved in MRP1-mediated drug transport. Role of glutathione

AU - Manciu, Liliana

AU - Chang, Xiu-Bao D

AU - Buyse, Frédéric

AU - Hou, Yue Xian

AU - Gustot, Adelin

AU - Riordani, John R.

AU - Ruysschaert, Jean Marie

PY - 2003/1/31

Y1 - 2003/1/31

N2 - Human multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette transporter family and transports chemotherapeutic drugs as well as diverse organic anions such as leukotriene LTC4. The transport of chemotherapeutic drugs requires the presence of reduced GSH. By using hydrogen/deuterium exchange kinetics and limited trypsin digestion, the structural changes associated with each step of the drug transport process are analyzed. Purified MRP1 is reconstituted into lipid vesicles with an inside-out orientation, exposing its cytoplasmic region to the external medium. The resulting proteoliposomes have been shown previously to exhibit both ATP-dependent drug transport and drug-stimulated ATPase activity. Our results show that during GSH-dependent drug transport, MRP1 does not undergo secondary structure changes but only modifications in its accessibility toward the external environment. Drug binding induces a restructuring of MRP1 membrane-embedded domains that does not affect the cytosolic domains, including the nucleotide binding domains, responsible for ATP hydrolysis. This demonstrates that drug binding to MRP1 is not sufficient to propagate an allosteric signal between the membrane and the cytosolic domains. On the other hand, GSH binding induces a conformational change that affects the structural organization of the cytosolic domains and enhances ATP binding and/or hydrolysis suggesting that GSH-mediated conformational changes are required for the coupling between drug transport and ATP hydrolysis. Following ATP binding, the protein adopts a conformation characterized by a decreased stability and/or an increased accessibility toward the aqueous medium. No additional change in the accessibility toward the solvent and/or the stability of this specific conformational state and no change of the transmembrane helices orientation are observed upon ATP hydrolysis. Binding of a non-transported drug affects the dynamic changes occurring during ATP binding and hydrolysis and restricts the movement of the drug and its release.

AB - Human multidrug resistance protein 1 (MRP1) is a member of the ATP-binding cassette transporter family and transports chemotherapeutic drugs as well as diverse organic anions such as leukotriene LTC4. The transport of chemotherapeutic drugs requires the presence of reduced GSH. By using hydrogen/deuterium exchange kinetics and limited trypsin digestion, the structural changes associated with each step of the drug transport process are analyzed. Purified MRP1 is reconstituted into lipid vesicles with an inside-out orientation, exposing its cytoplasmic region to the external medium. The resulting proteoliposomes have been shown previously to exhibit both ATP-dependent drug transport and drug-stimulated ATPase activity. Our results show that during GSH-dependent drug transport, MRP1 does not undergo secondary structure changes but only modifications in its accessibility toward the external environment. Drug binding induces a restructuring of MRP1 membrane-embedded domains that does not affect the cytosolic domains, including the nucleotide binding domains, responsible for ATP hydrolysis. This demonstrates that drug binding to MRP1 is not sufficient to propagate an allosteric signal between the membrane and the cytosolic domains. On the other hand, GSH binding induces a conformational change that affects the structural organization of the cytosolic domains and enhances ATP binding and/or hydrolysis suggesting that GSH-mediated conformational changes are required for the coupling between drug transport and ATP hydrolysis. Following ATP binding, the protein adopts a conformation characterized by a decreased stability and/or an increased accessibility toward the aqueous medium. No additional change in the accessibility toward the solvent and/or the stability of this specific conformational state and no change of the transmembrane helices orientation are observed upon ATP hydrolysis. Binding of a non-transported drug affects the dynamic changes occurring during ATP binding and hydrolysis and restricts the movement of the drug and its release.

UR - http://www.scopus.com/inward/record.url?scp=0037474237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037474237&partnerID=8YFLogxK

U2 - 10.1074/jbc.M207963200

DO - 10.1074/jbc.M207963200

M3 - Article

C2 - 12424247

AN - SCOPUS:0037474237

VL - 278

SP - 3347

EP - 3356

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 5

ER -